All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the main challenges when evaluating novel agents for GvHD prophylaxis?
Bookmark this article
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Robert Zeiser, Medical Center - University of Freiburg, Freiburg, DE. We asked, What are the main challenges when evaluating novel agents for GvHD prophylaxis?
What are the main challenges when evaluating novel agents for GvHD prophylaxis?
The main challenge identified by Zeiser is that only a small percentage of patients on prophylaxis treatment develop GvHD, making large trials challenging. In addition, the conditioning regimens used in different institutions vary, making it difficult to compare data from trials.
More about...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox